Dr. Madan Comments on Recent Research Involving Obesity Contributors

In recent studies, connections between obesity, diabetes, heart disease and cancer have been made, and many suggestions made regarding adiponectin and leptin treatments. Dr. Atul Madan outlines and comments on research focused on important hormones involved in the buildup of fat, and the possible benefits of the LAP-BAND® system for those suffering from obesity.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Dr. Madan is a member of American Society of Metabolic and Bariatric Surgery, Society of Laparoendoscopic Surgeons, and Society of American Gastrointestinal and Endoscopic Surgeons.

Dr. Atul Madan MD is a world-renowned expert in laparoscopic and bariatric program.

Los Angeles, California (PRWEB) February 04, 2013

Dr. Madan outlines and comments on research focused on important hormones involved in the buildup of fat, and the possible benefits of the LAP-BAND® system for those suffering from obesity. Many studies have been made in the last 10 years on the national issue of overweight, obesity, and its contributors. However, a new Korean study focused on the relationship between type 2 diabetes, insulin resistance, and peripheral fat has shed some light on the factors contributing to obesity that make losing weight more complex than diet and exercise habits. Eighty-three Korean women were studied, with an average age of 56, with an existing issue with type 2 diabetes. In order to understand the study, it may be necessary to review historical research breakthroughs in obesity contributors.

In 1995, MIT biology professor named Harvey Lodish made a breakthrough in his studies on the biology of fat cells and muscle tissue. The Lodish lab created a clone of adiponectin, which is a naturally occurring fat cell hormone. The lab's discovery of adiponectin's ability to boost the burning of fatty acids went a long way toward opening up research on the toxic effects of obesity, although the original research was done on lab mice.

A lack of adiponectin can trigger another hormone (TNFa), which reduces the body's ability to burn up fatty acids. (The inflammatory TNFa hormone can be linked to issues of arthritis and cancer, and genetically deficient levels of adiponectin can be a trigger for other conditions linked to obesity, such as heart disease.) If the fatty acids are stored in fat cells, the body can eventually burn the fat. However, if the fatty acids are allowed to build up in the blood, muscles can become insulin resistant, and glucose can build up to high levels, which contributes to type 2 diabetes. The Lodish lab recently sold its rights to EMD Serono (a large biotech division of Merck) to further examine this discovery.

According to the Harvard professor of genetics and metabolism, Gökhan Hotamisligil, the real issue is the body's immunity response that results in muscle inflammation, which can be enhanced by lack of exercise. “Excess calories affect the fat cells in such a way that they mount an immune response...You’re activating the immune system without a legitimate pathogen”. The body's stress level increases, which triggers the body to produce more inflammation reduction, which then interferes with proper metabolism.

Bariatric surgeon Dr. Atul Madan points to these studies to outline the dangers of fat in obesity. Serious research has been done since 1994 on a hormone named leptin, which acts as the 'stop' sign for food intake. Leptin deficiencies can result in an inability to know when to stop eating, which can add to fatty acid buildup and high glucose levels, which can then trigger increased risk for diabetes, and muscle inflammation that keeps the body at a low metabolism level. Although both leptin and adiponectin are produced by fat cells up to a certain level, obesity causes the body to stop producing adiponectin and build up leptin resistance. Obesity then becomes an unending cycle, not unlike cancer that is often caused by the body's overreaction to an infection or inflammation.

The Korean study supported the above findings, and added a new twist. (“As in previous studies, the association between total fat mass and adipokines-especially adiponectin and leptin-has been reconfirmed.”) LAP-BAND® surgeon Dr. Atul Madan suggests that this study not only shows the dangers of fat in type 2 diabetes patients struggling with obesity, but it also shows that fat distribution on the abdomen or legs (or “peripheral fat mass”) can aggravate other existing health issues, such as cardiovascular complications. Further, Dr. Madan suggests that on simple injections of adiponectin or leptin would not wholly treat the patient's obesity or diabetes, as the Korean study found that not all diabetes is obesity-related, and that “adiponectin alone does not sufficiently explain the problems resulting from diabetes”.

One way of stopping the cycle is the LAP-BAND® Adjustable Gastric Banding System (LAP-BAND®). Although it is not the only obesity treatment method, lap band surgeon Dr. Atul Madan has done significant research on weight loss and gastrointestinal surgery, and he says that it may be one of the most long-term effective methods for maintaining weight loss. The LAP-BAND® system has been approved as the first gastric banding method approved by the U.S. FDA (Food and Drug Administration) for weight reduction, and many have enjoyed long-term weight loss after its insertion.

Dr. Madan has written 175 articles, and was the first in Memphis to perform a laparoscopic gastric bypass. To date, he has performed over 2,000 laparoscopic gastric bypasses and gastric banding procedures. As the former Chief of Laparoendoscopic and Bariatric Surgery Division at the University of Miami, he may well be considered an expert in his field. Dr. Madan's patient reviews are consistently high, and he received the 2011 and 2012 Patients' Choice Award.

For more information on Dr. Atul Madan or the LAP-BAND procedure, call 1-800-472-4900, or review more on Dr. Madan on http://www.obesityhelp.com/profiles/bariatric-surgeon/dr-atul-madan/.


Contact